Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloid Leukaemia

Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Bone Marrow Transplantation volume 32, pages 993–999 (2003)Cite this article

Summary:

To determine the results of allogeneic hematopoietic stem cell (HSC) transplantation for chronic myelogenous leukemia (CML) at various stages of the disease in children, a retrospective analysis was carried out on the outcome of transplants performed on 76 children and teenagers with CML between 1982 and 1998. In all, 60 patients were transplanted from a matched sibling donor (MSD) and 16 from a matched unrelated donor (MUD). There was a higher incidence of acute graft-versus-host disease after MUD transplantation (P<10−3). The main cause of death was transplant-related toxicity in both groups. In MSD recipients, the probability of relapse at 5 years for patients transplanted in the first chronic phase was lower than in patients transplanted in the advanced phase (relative risk (rr)=5.90; 95% confidence interval (CI), 1.85–18.82, P<0.01). The estimated 5-year event-free survival (EFS) rate was higher after MSD vs MUD transplantation (61% (95% CI, 48–73%) vs 27% (95% CI, 4–49%), rr=0.25, P<10−3). In children transplanted from MSD, the 5-year EFS was higher when transplantation was performed in the first chronic phase vs the advanced phases (73% (95% CI, 59–87%) vs 32% (95% CI, 10–54%), P<10−3). Disease status at transplantation was the unique factor influencing survival in patients undergoing transplantation from MSD with a better outcome for those transplanted in the first chronic phase. Allogeneic HSC offers a possibility of curing childhood CML with a significant advantage for patients transplanted in chronic phase using a human leukocyte antigen-identical sibling donor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Guilhot F, Chastang C, Michallet M et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223–229.

    Article  CAS  PubMed  Google Scholar 

  2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541–1548.

  3. Druker B, Talpaz M, Resta D et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  PubMed  Google Scholar 

  4. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  PubMed  Google Scholar 

  5. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536.

    CAS  PubMed  Google Scholar 

  6. Klingebiel T, Creutzig U, Dopfer R et al. Bone marrow transplantation in comparison with conventional therapy in children with adult type chronic myelogenous leukemia. Bone Marrow Transplant 1990; 5: 317–320.

    CAS  PubMed  Google Scholar 

  7. Gamis AS, Haake R, McGlave P, Ramsey NK . Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993; 11: 834–838.

    Article  CAS  PubMed  Google Scholar 

  8. Munoz A, Bureo E, Ortega JJ et al. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Haematologica 1998; 83: 981–984.

    CAS  PubMed  Google Scholar 

  9. Speck B, Bortin MM, Champlin R . Bone marrow transplantation for chronic myelogenous leukemia. Lancet 1984; i: 665–668.

    Article  Google Scholar 

  10. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  11. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  12. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 1352: 1087–1092.

    Article  Google Scholar 

  13. Horibe K, Tsukimoto I, Ohno R . Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia 2001; 15: 1256–1261.

    Article  CAS  PubMed  Google Scholar 

  14. Clift RA, Bukner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 184: 2036–2043.

    Google Scholar 

  15. Kantarjian HM, Giles FJ, O'Brien S et al. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer 2000; 89: 1647–1658.

    Article  CAS  PubMed  Google Scholar 

  16. Hehlmann R, Hochhaus A, Kolb HJ et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677.

    CAS  PubMed  Google Scholar 

  17. Gale RP, Hehlmann R, Zhang MJ et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myeloid leukemia. Blood 1998; 91: 1810–1819.

    CAS  PubMed  Google Scholar 

  18. Goldman J, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202–209.

    Article  CAS  PubMed  Google Scholar 

  19. Van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553–560.

    Article  CAS  PubMed  Google Scholar 

  20. Enright H, Davis SM, Defor T et al. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor and chronic graft-versus-host disease are protective. Blood 1996; 88: 714–720.

    CAS  PubMed  Google Scholar 

  21. The Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol 1999; 17: 1858–1868.

  22. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207–212.

    Article  CAS  PubMed  Google Scholar 

  23. Dini G, Lamparelli T, Rondelli et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia. Br J Haematol 1998; 102: 544–552.

    Article  CAS  PubMed  Google Scholar 

  24. Pertersdorf EW, Longton GM, Anasetti C et al. The significance of HLA6DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606–1613.

    Google Scholar 

  25. Bornhausen M, Kiehl M, Siegert W et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukemia: a retrospective analysis. Br J Haematol 2001; 115: 119–124.

    Article  Google Scholar 

  26. Weisdorf DJ, Anasetti C, Antin JH et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99: 1971–1977.

    Article  CAS  PubMed  Google Scholar 

  27. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.

    Article  CAS  PubMed  Google Scholar 

  28. McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: the 9 year's experience of the National Donor Program. Blood 2000; 95: 2219–2225.

    CAS  PubMed  Google Scholar 

  29. Millot F, Brice P, Philippe N et al. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia. J Pediatr Hematol Oncol 2002; 24: 18–21.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Hospitalier Universitaire, Poitiers, France

    F Millot, A Rome, J Guilhot & F Guilhot

  2. Hôpital Saint Louis, Paris, France

    H Esperou

  3. Centre Hospitalier Universitaire, Vandoeuvre, France

    P Bordigoni

  4. Hôpital Jeanne de Flandre, Lille, France

    J-H Dalle

  5. Hôpital Edouard Herriot, Lyon, France

    M Michallet

  6. Hôpital La Timone, Marseille, France

    G Michel

  7. Institut Gustave Roussy, Villejuif, France

    J L Bourhis

  8. Hôpital Henri Mondor, Créteil, France

    M Kuenz

  9. Institut Paoli Calmette, Marseille, France

    D Blaise

  10. Hopital La Tronche, Grenoble, France

    F Garban

  11. Centre Hospitalier Universitaire, Besançon, France

    E Plouvier

Authors
  1. F Millot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Esperou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Bordigoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J-H Dalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J L Bourhis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Kuenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Garban
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Plouvier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Rome
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Guilhot
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F Guilhot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Millot.

Appendix 1

Appendix 1

Participating centers and center directors:

Hopital Saint Louis, Paris (Pr Gluckmann, Dr Esperou); Hopital Pellegrin, Pessac (Pr Reiffers); Centre Hospitalier Universitaire, Grenoble (Dr Garban); Hopital Intercommunal, Créteil (Dr Kuentz); Institut Paoli Calmette, Marseille (Pr Blaise); Centre Hospitalier Universitaire, Besançon (Pr Cahn, Dr Plouvier); Hopital Edouard Herriot, Lyon (Pr Michallet); Hopital d'enfants, Vandoeuvre (Pr Bordigoni); Centre Hospitalier Universitaire, Nantes (Pr Milpied); Institut Gustave Roussy, Villejuif (Dr Bourhis); Hopital Necker, Paris (Pr Fisher); Hopital Robert Debré, Paris (Pr Vilmer); Hopital La Timone, Marseille (Pr Michel); Centre Hospitalier Universitaire, Dijon (Pr Caillot); Hopital Charle Nicolle, Rouen (Pr Vannier); Hopital Jean Bernard, Poitiers (Pr Guilhot); Hopital Calmette, Lille (Pr Jouet); Centre Hospitalier Universitaire, Clermont Ferrand (Pr Demeocq); CHU Strabourg (Dr Lioure); Centre Hospitalier Universitaire, Saint-Etienne (Pr Guyotat); Centre Hospitalier Universitaire, Toulouse (Pr Attal, Dr Rubie); Hopital Pitié Salpétrière, Paris (Pr Vernant).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Millot, F., Esperou, H., Bordigoni, P. et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 32, 993–999 (2003). https://doi.org/10.1038/sj.bmt.1704255

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704255

Keywords

This article is cited by

Search

Advanced search

Quick links